ArticleFrontiers in pharmacology2026
UNC93B1 drives IL-6/STAT3-dependent tumor-macrophage crosstalk and epithelial-mesenchymal transition in breast cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lipid metabolic reprogramming is increasingly recognized as a driver of breast cancer progression; however, how lipid metabolism-associated risk states are translated into immune remodeling and epithelial-mesenchymal transition (EMT) remains unclear. This study aimed to identify a lipid metabolism-related regulator that mediates tumor-macrophage crosstalk and to experimentally define its role in breast cancer progression. Methods: Lipid metabolism-related immune regulatory candidates were identified through integrated bulk transcriptomic, machine-learning, single-cell, and spatial transcriptomic analyses. UNC93B1 was prioritized for experimental validation using immunohistochemistry, gain- and loss-of-function assays, tumor cell-macrophage co-culture, ELISA, IL-6 neutralization, and STAT3 inhibition/rescue experiments. Results: Integrated multi-omics analysis prioritized UNC93B1 as a lipid metabolism-associated immune regulatory hub in breast cancer. UNC93B1 was associated with high lipid metabolism risk status, invasive tumor phenotypes, and stronger expression in aggressive molecular contexts, particularly HER2-enriched and triple-negative breast cancer samples. Single-cell and spatial transcriptomic analyses further linked UNC93B1 to myeloid/macrophage-enriched states, M2-like macrophage polarization, and Toll-like receptor-related immune niches. Experimentally, UNC93B1 knockdown suppressed breast cancer cell proliferation, migration, invasion, STAT3 activation, and EMT, whereas UNC93B1 overexpression produced the opposite effects. In tumor cell-macrophage co-culture systems, tumor cell-derived UNC93B1 enhanced IL-6 secretion, activated STAT3 signaling in macrophages, and promoted M2-like polarization. Reciprocally, macrophage-associated IL-6/STAT3 signaling reinforced EMT and invasive behavior in breast cancer cells. IL-6 neutralization and STAT3 inhibition markedly disrupted this paracrine feedback loop, confirming that UNC93B1 promotes breast cancer progression through an IL-6/STAT3-dependent tumor-macrophage crosstalk axis. Conclusion: This study identifies UNC93B1 as a macrophage-associated immune regulatory factor linked to lipid metabolism-related risk in breast cancer. Integrated multi-omics analyses and functional experiments demonstrate that UNC93B1 promotes IL-6/STAT3-dependent tumor-macrophage communication, thereby enhancing M2-like macrophage polarization, EMT activation, and invasive tumor behavior. These findings support UNC93B1 as a potential biomarker and intervention target in immunologically aggressive breast cancer. However, the direct role of UNC93B1 in lipid metabolic remodeling remains to be validated through lipidomic and metabolic flux analyses, and its tumor- and microenvironment-dependent effects require further confirmation in orthotopic or immune-competent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.